Latest Antiandrogens Stories
HORSHAM, Pa., April 28, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the U.S.
SILVER SPRING, Md., April 28, 2011 /PRNewswire-USNewswire/ -- The U.S.
Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.
SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo.
WASHINGTON, Oct. 1 /PRNewswire-USNewswire/ -- U.S. Centers for Disease Control and Prevention officials have disclosed that two mifepristone (RU-486)-induced deaths occurred in the past two years, bringing the total number of reported death related to RU-486 to 12.
SAN FRANCISCO and TOKYO, Sept. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
LOS ANGELES, Sept.
In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.
SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGONÂ® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr.
- A serpent whose bite was fabled to produce intense thirst.